Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12819665 | 0.98 | PIK3R1 (1.00) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12820305 | 0.84 | PIK3R1 (1.00) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12819468 | 0.82 | PIK3R1 (0.69) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12819971 | 0.82 | PIK3R1 (0.79) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12820304 | 0.79 | PIK3R1 (0.67) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1445083 | 0.78 | PIK3R1 (1.00) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16881779 | 0.77 | PIK3CA (0.63) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12819914 | 0.77 | PIK3R1 (0.61) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL14725955 | 0.76 | PIK3CA (0.62) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL14667172 | 0.76 | PIK3R1 (1.00) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480549-B1 | Fused imidazo[3,2-d]pyrazines as PI3 kinase inhibitors | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-04-08 | — | — | EP | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| WO-2011036461-A1 | FUSED IMIDAZO [3, 2 - D] PYRAZINES AS PI3 KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCΌLOGICAS (CNIO) (ES) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | PIK3R1 171/4885PIK3CA 2/4885PIK3CD 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.